1 October 2010 in The Journal of Nutrition
JLJacqueline A. E. Langius
MSMarieke D. Spreeuwenberg
BBB. Mary E. von Blomberg
+2
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), (n-3) fatty acids from fish oil, have immune-modulating effects and may improve nutrition
23 May 2007 in The Journal of Physiology
GLGerdien C. Ligthart‐Melis
Gerdien C. Ligthart‐Melis
11 January 2012 in European Journal of Clinical Nutrition
Background/Objectives: Subjects/Methods: Results: Conclusion:
1 July 2017 in Clinical Breast Cancer
1 May 2008 in The American Journal of Clinical Nutrition
GLGerdien C Ligthart-Melis
Background: A metabolic relation exists between glutamine and arginine, 2 amino acids with properties that enhance the recovery of seriously ill patients. It is possible that glutamine exerts part of its beneficial effects by enhancing the availability of arginine. Objectives: We aimed to quantify under postabsorptive conditions the metabolic pathway of plasma glutamine into arginine via the intermediate citrulline and to establish the contribution of the kidneys to the synthesis of arginine. Design: The study was conducted in patients during surgery. The metabolism of glutamine, citrulline, and arginine was studied by using intravenous administration of stable isotope tracers of the amino acids. Results were interpreted by using established equations. Parametric tests were used to test and correlate results. P < 0.05 was regarded as significant. Results: Mean (±SE) whole-body plasma turnover rates of glutamine, citrulline, and arginine were 240 ± 14, 6.2 ± 0.6, and 42 ± 2.9 μmol · kg−1 · h−1, respectively (P < 0.01). Plasma turnover of citrulline derived from glutamine was shown to be 5.1 ± 0.7 μmol · kg−1 · h−1, and arginine derived from citrulline was shown to be 4.9 ± 0.9 μmol · kg−1 · h−1 (P < 0.01). The contribution of plasma glutamine to plasma arginine derived from plasma citrulline was calculated to be 64%. The kidneys were observed to take up >50% of circulating plasma citrulline and to release equimolar amounts of arginine into plasma. Conclusions: This study shows that glutamine is an important precursor for the synthesis of arginine in humans. It also provides a firm basis for future studies exploring the effect of a treatment dose and the route of administration (enteral or parenteral) of glutamine.
22 February 2005 in Hepatology
JSJoost R. M. van der Sijp
Asymmetric (ADMA) and symmetric dimethylarginine (SDMA) inhibit production of nitric oxide. The concentration of both dimethylarginines is regulated by urinary excretion, although ADMA, but not SDMA, is also subject to degradation by dimethylarginine dimethylaminohydrolase, which is highly expressed in the liver but also present in the kidney. The exact roles of the human liver and kidney in the metabolism of dimethylarginines are currently unknown. Therefore, we aimed to investigate renal and hepatic handling of ADMA and SDMA in detail in 24 patients undergoing hepatic surgery. To calculate net organ fluxes and fractional extraction (FE) rates, blood was collected from an arterial line, the portal vein, hepatic vein, and renal vein, and blood flow of the hepatic artery, portal vein, and renal vein was determined using Doppler ultrasound techniques. Results showed a significant net uptake (median [IQR]) of ADMA in both the liver (9.6 nmol/min [5.6–13.2]) and the kidney (12.1 nmol/min [1.3–17.1]). SDMA uptake was present not only in the kidney (12.7 nmol/min [3.5–25.4]), but also in the liver (7.7 nmol/min [2.8–16.4]). FE rates of ADMA for the liver and kidney were 5.0% (3.5%–7.4%) and 8.4% (1.3%–13.9%), respectively. For SDMA, hepatic and renal FE rates were 3.4% (2.1%–7.5%) and 12.5% (3.6%–16.2%), respectively. In conclusion, this study gives a detailed description of the hepatic and renal elimination of dimethylarginines and shows that the clearing of SDMA is not only confined to the kidney, but the human liver also takes up substantial amounts of SDMA from the portal and systemic circulation. (HEPATOLOGY 200541:559–565.)